Catalog No. |
TD-YP115026 |
Species reactivity |
General |
Applications |
Research Grade Biosimilar |
Host species |
Chimeric |
Isotype |
IgG1-kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
Ganglioside GD2 |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
CAS: 65988-71-8 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
14.18 mAb, 14.18-IL-2, EMD273063, EMD-273063, Hu14.18-IL-2, Hu14.18-IL2, anti-GD2 fused to IL2, hu14.18-IL2, hu14.18-Interleukin-2 fusion protein, CAS: 2131168-99-3 |
Background |
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |